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Abstract. This study demonstrates high-efficiency steril-
isation of single cancer cells in a SCID mouse model of
leukaemia using rituximab, a monoclonal antibody that
targets CD20, labelled with terbium-149, an alpha-emit-
ting radionuclide. Radio-immunotherapy with 5.5 MBq
labelled antibody conjugate (1.11 GBq/mg) 2 days after
an intravenous graft of 5·106 Daudi cells resulted in tu-
mour-free survival for >120 days in 89% of treated ani-
mals. In contrast, all control mice (no treatment or treat-
ed with 5 or 300 µg unlabelled rituximab) developed
lymphoma disease. At the end of the study period,
28.4%±4% of the long-lived daughter activity remained
in the body, of which 91.1% was located in bone tissue
and 6.3% in the liver. A relatively high daughter radioac-
tivity concentration was found in the spleen
(12%±2%/g), suggesting that the killed cancer cells are
mainly eliminated through the spleen. This promising
preliminary in vivo study suggests that targeted alpha
therapy with 149Tb is worthy of consideration as a new-
generation radio-immunotherapeutic approach.
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Introduction
Single cancer cells in circulation and small cancer cell
clusters can be effectively targeted with radio-immuno-
conjugates that specifically bind to the cells and deliver
the required dose. Alpha-emitting radioisotopes may be
of great advantage in this kind of therapy because of
their higher linear energy transfer (LET) value and, con-
sequently, the shorter penetration track compared to β−-
and γ-radiation [1]. It has been shown that only a very
few alpha-hits are sufficient to kill a cell [2], and the
short range of the alpha particles increases the safety
profile of alpha-emitters because non-specific irradiation
of normal tissue (or plasma) around the target cells is
greatly reduced or absent [3]. Additionally, since single
cancer cells in circulation are immediately accessible to
the injected (i.v.) radio-immunoconjugate, the shorter
half-lives of a few alpha-emitting radioisotopes may be
advantageous [4]. Only a small number of alpha-emitting
radionuclides fulfill the requirements for this specific nu-
clear medical application: 225Fm, 225Ac, 224Ra, 223Ra,
213Bi, 212Bi, 211At and 149Tb. Especially 213Bi and 211At
have proven to be very promising candidates, because of
the availability (225Ac/213Bi generator) and the conve-
nient half-life of 7.2 h (211At) (for example see refs. [5,
6]).
Today, new approaches in conjugation with chelating
ligands allow the stable labelling of macromolecules
(such as monoclonal antibodies) or peptides with metal-
lic radionuclides. The first clinical proof-of-principle of
targeted alpha therapy was observed using the HuM195
antibody labelled with the short-lived (46 min) 213Bi ra-
dionuclide [7], which is a daughter product in the decay
chain of 225Ac (10 days). The mother nuclide, 225Ac, is
itself considered a candidate for targeted alpha therapy
(TAT), and corresponding studies are ongoing [3, 8]. A
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potential drawback with use of 225Ac is the possibility
that the short-lived alpha-emitting daughter nuclides in
the decay chain will escape from the place of origin,
leading to uncontrolled deposition of the radiation dose
throughout the body.
The partial alpha-emitting nuclide 149Tb (T1/2=
4.118 h, Eα=3.967 MeV; range in tissue =28 µm), which
belongs to the group of rare earth elements, has been
proposed as a promising alpha-emitter for TAT [4, 9, 10,
11]. Its chemical behaviour is very close to that of yttri-
um or lutetium, whose isotopes 90Y and 177Lu are cur-
rently the most predominant metallic radionuclides used
in clinical radio-immunotherapy (RIT) [12]. Thus, exist-
ing approaches for labelling of chelated bioconjugates
with these metallic radionuclides, as well as 166Ho,
153Sm, 213Bi or 225Ac, can be directly applied to 149Tb.
Previous in vitro studies have revealed certain advan-
tages of 149Tb over 213Bi for treating single cells [13].
These advantages, which relate to the lower energy and
higher LET of alpha particles emitted by 149Tb, partially
compensate for its lower alpha branching (17%, Fig. 1)
[13, 14]. The longer half-life of 149Tb (4.12 h) compared
with 213Bi (46 min) represents a clear advantage, both at
the level of bioconjugate preparation and for administra-
tion to patients for tumour cell targeting. On the other
hand, the fate of long-lived daughter products that ap-
pear during the decay of 149Tb would need to be consid-
ered carefully in the dosimetry (Fig. 1).
In this paper we describe the first in vivo survival
study using a 149Tb-based TAT approach in SCID (severe
combined immuno-deficient) mice. SCID mice, being de-
ficient in T and B cell immune defence, easily develop
tumour masses after injection of cancer cells. Daudi cells,
which are derived from a human Burkitt lymphoma, are
one of several cell lines that can rapidly colonise these
mice. Depending on the injection route, different tumour
types can develop. As few as 100 injected (i.v.) Daudi
cells are sufficient to kill SCID mice due to tumour de-
velopment [15]. Since Daudi cells express a high number
of CD20 antigens, rituximab can target Daudi cells with
high specificity. Thus, an early stage of this model, within
3 days of i.v. xenograft, before the formation of manifest-
ed tumour nodes, provides an ideal system to study the
proposed advantages of 149Tb-based TAT.
The primary aim of this work was to examine the effi-
cacy of 149Tb-labelled rituximab to specifically kill cir-
culating single cancer cells or small cell clusters in vivo.
SCID mice following i.v. xenograft with Daudi cells re-
present a perfect model for leukaemia [16]. Our experi-
mental model involves TAT intervention within 3 days of
i.v. xenograft, and hence before the formation of mani-
fested tumour nodes, which we did not intend to target in
this study. According to our experimental hypothesis,
mice xenotransplanted with a lethal number of Daudi
cells will survive provided that a sufficient dose of 149Tb
has been delivered via rituximab to all tumour cells. Sec-
ondly, we aimed to obtain information about the behav-
iour of the daughter products generally formed in the ra-
dioactive decay chain. The 17% alpha decay mode of the
149Tb generates an isobar chain with the mass number
A=145 with 145Eu (T1/2=5.93 days), 145Sm (T1/2=340
days) and 145Pm (T1/2=17.7 years). The EC-process decay
chain of 149Tb forms the stable 149Sm passing the 149Gd
(T1/2=9.28 days) and the 149Eu (T1/2=93.1 days) ([17],
Fig. 1). Most of these isotopes are easily detectable using
high-resolution gamma spectroscopic techniques (Fig. 1).
In particular, we expected that differences in daughter
isotope behaviour induced by the different decay modes
(alpha versus EC) would be apparent.
Materials and methods
Cell line. Daudi cells (ATCC Nr. CCL-213) were used to simulate
a leukaemia model in mice. The cells were cultured in RPMI 1640
medium supplemented with 10% heat-inactivated fetal calf serum
and 0.5% penicillin (10,000 U/ml)/streptomycin (10 mg/ml) (Sig-
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Fig. 1. Simplified decay scheme of 149Tb and the list of the most
relevant gamma transitions (adopted from [17]). Note that the de-
cay of the 149Tb itself as well as the first daughter products is ac-
companied by relatively intense gamma emission, while the lon-
ger-lived daughter products of the second and third generations
show very little gamma contribution
ma-Aldrich). The cell suspension to be injected into mice was pre-
pared by centrifuging the culture for 3 min at 1,200 rpm, washing
with PBS and re-suspending in PBS at 2.5·107 cells per ml.
Antibody conjugate. Rituximab antibody (Rituxan; IDEC Pharma-
ceuticals, San Diego, and Genentech Inc, San Francisco) is a
chimeric version of anti CD-20 monoclonal antibody consisting of
human IgG1 constant domains and murine variable domains. The
rituximab antibody conjugated with SCN-CHX-A-DTPA (2-(4-
isothiocyanatobenzyl)-cyclohexyl-diethylenetriamine penta-acetic
acid), used in this study, was kindly provided by Dr. D.A. Schein-
berg (Memorial Sloan Kettering Cancer Center, New York).
Radionuclide. The 149Tb was produced using the on-line isotope
separator facility ISOLDE at CERN (Geneva, Switzerland) [18,
19]. A tantalum-foil target (120 g/cm2) was irradiated with 1.0- or
1.4-GeV protons delivered from the CERN PS-Booster accelera-
tor. The radio-lanthanides generated in the spallation process are
released from the target material, which is kept at about 2,200°C,
ionised by surface ionisation and accelerated to 60 keV. From the
obtained radioactive ion beams, the A=149 isobars (149Dy, 149Tb
and molecular ions 133CeO+ and 133LaO+) were implanted
(60 keV) and thus collected in thin layers of KNO3 (10 mg/cm2)
on aluminium backings. The 149Tb was separated from its daugh-
ters (149Gd and 145Eu) and the pseudo-isobars 133Ce and 133La by
cation exchange chromatography using Aminex A5 resin and α-
hydroxyisobutyric acid as eluent. A typical elution chromatogram
is presented in Fig. 2. The 149Tb fraction (150–200 µl) was evapo-
rated to dryness and re-dissolved in 50 µl of 100 mM HCl. The fi-
nal 149Tb concentration was 2 GBq/ml (54 mCi/ml) at the end of
chromatographic separation (EOS).
Labelling procedure. From 25 to 40 µl of the 149Tb solution char-
acterised above was used immediately for the labelling procedure.
The pH was adjusted to 5.5 by adding 60 µl of 3 M CH3COONH4
solution, followed by the addition of 10 µl (40 mg/ml) ascorbic
acid. After adding 5 µl of a stock solution of the chelated antibody
in PBS (10 mg/ml), the mixture was incubated for 10 min at room
temperature, before dilution to a final volume of 1.0 ml in PBS-
1% human serum. The radiochemical purity of the labelled ritux-
imab was determined by instant thin-layer chromatography
(1.5×15 cm ITLC-SG strips, Gelman Instrument Company) using
0.1 M acetate buffer of pH 6 as a mobile phase and the linear ana-
lyser (Berthold). The injection of the radio-immunoconjugate into
the mice was performed 1 h after EOS. The in vitro behaviour of
the labelled bioconjugate (immunoreactivity, cell binding, cell
killing efficiency) has been described in a previous paper [14].
With the same antibody we observed up to 55% cell binding with-
out extrapolation to infinite antigen excess.
Mice survival studies. The in vivo studies were performed using
26 female SCID mice (C.B.-17/ICR, Iffa Credo) under the authori-
sation Nr: GE 31.1.1049/1879/II. The mice, which were 8 weeks
old at the start of the experiment and weighed 20 g on average,
were kept in sterile, ventilated boxes. Before injecting cells and
antibodies, mice were anaesthetised by i.p. (intraperitoneal) injec-
tion of 10 ml per kg (typically 0.2 ml) of an anaesthetic (2.4 ml
Ketasol 50, 0.8 ml Rompun, 6.8 ml 0.9% NaCl). Each mouse re-
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Fig. 2. Separation of the A=149 isobars obtained in the on-line
isotope separation process at ISOLDE by using cation exchange
chromatography. Column: Aminex A 5 in NH4+ form, 3×60 mm2,
eluent: α-HIBA, elution speed: 100 µl/min (one drop =35 µl= one
fraction). The isotopic content of each fraction has been deter-
mined by high-resolution gamma ray spectrometry
Table 1. Summary of the in vivo experiments on SCID mice xenotransplanted with Daudi cells and treated by immunotherapy or radio-
immunotherapy with 149Tb-labelled rituximab
SCID mice groups
Group 1 Group 2 Group 3 Group 4 (control group)
No. of mice per group 6 4 9 6
First i.v. injection 5·106 Daudi cells
Second i.v. injection 5 µg rituximab 300 µg rituximab 5 µg 149Tb-labelled None
2 days after Daudi cell rituximab (5.55 MBq)
inoculation
Results during follow-up 17% developed 50% developed 89% had no 50% developed 
(up to 120 days after macroscopic tumours, macroscopic tumours, pathological changes, macroscopic tumours, 
the therapy) 83% showed paralysis 50% showed paralysis 11% had abdominal 50% showed paralysis 
or weight loss or weight loss tumour growth or weight loss
ceived 5·106 Daudi cells by injection of 0.2 ml cell suspension in
PBS into the tail vein. Two days after xenotransplantation the
mice were divided into four groups: the first group received 5 µg
rituximab in 0.1 ml PBS i.v.; the second group, 300 µg rituximab
in 0.1 ml PBS i.v.; and the third group, 5.5 MBq 149Tb-CHX-A-
DTPA-rituximab radio-immunoconjugate (5 µg labelled rituximab
in 0.2 ml, i.v.); the fourth group was left without any treatment. A
summary of the in vivo study is presented in Table 1. According to
the authorised protocol, the mice were surveyed for 120 days:
their behaviour was logged each day, their condition was super-
vised once a week by a veterinarian, and they were weighed three
times a week. At the appearance of obvious signs of paralysis, vis-
ible tumour masses or a weight loss of >15%, the mice were sacri-
ficed. One mouse was sacrificed shortly after injection (2 h p.i.)
and kept deep-frozen for later analysis, in order to act as a refer-
ence for later quantification of the daughter radioactivity distribu-
tion.
Retention and daughter radioactivity distribution. Organ samples
were taken from the sacrificed mice and the radioactivity concen-
tration of the long-lived daughter products was determined by us-
ing high-resolution gamma spectroscopy (18% HP-Ge detector in
combination with the Gamma spectrometer Genie 2000, Canberra).
Whole, intact mice, as well as isolated organ samples, were mea-
sured. Since the radioactivity content of the samples was essential-
ly very low, long measuring times (between 1 and 24 h) were ap-
plied.
Statistical analysis. The survival of animals until sacrifice because
of disease development or the end of the experiment (no disease
development) was compared between the different groups accord-
ing a Kaplan Meier analysis using the Lee-Desu evaluation of the
Unistat 3.0 statistical package (Megalon, Novato CA, USA).
Results
Preparation of labelled rituximab
Mass-separated and radiochemically pure 149Tb was ob-
tained after chromatographic separation of the collected
isobars with mass number A=149 at the on-line mass
separator facility at CERN (Fig. 2). The overall time
needed for the radiochemical separation and the labelling
procedure was 1 h. Radiolabelling of the rituximab with
this 149Tb-preparation was almost quantitative (>99%)
within 10 min incubation time. The obtained preparation
was thus ready for injection without further purification.
The radioactivity concentration of the labelled antibody
solution was 27.8 MBq/ml (0.75 mCi/ml), while the spe-
cific activity was 1.11 GBq/mg (30 mCi/mg) at the mo-
ment of injection.
Survival in a SCID mouse model of leukaemia
We set out to evaluate the efficacy of 149Tb-based TAT
using a SCID mouse model of leukaemia [16]. Our ex-
perimental model involved the i.v. xenografting of a le-
thal number of Daudi cells followed by TAT intervention
at a time point when most of the Daudi cells would be
expected to remain in circulation, and before the appear-
ance of manifested tumours, which we did not intend to
target in this study. Survival data over a period of 4
months for treated mice and controls are shown in Fig. 3.
All mice in the untreated control group developed clear
signs of Burkitt lymphoma and were consequently sacri-
ficed within 37 days. Fifty percent of them developed
visible macroscopic tumours while the others were sacri-
ficed when they showed clear signs of paralysis or a
weight loss >15% of the initial body weight (Table 1).
The injection of a single, low dose of rituximab
(5 µg/animal) did not show any therapeutic effect, and all
mice in this group had to be sacrificed within 43 days.
As can be seen from Fig. 3, the survival curves of this
group and the control group (untreated mice) are almost
identical. Of the mice in this group, 83% expressed obvi-
ous signs of paralysis or weight loss of >3 g, while 17%
developed visible macroscopic tumour masses.
A different survival pattern was observed after treat-
ment with a high dose of rituximab (300 µg per animal,
corresponding to 15 mg/kg). Although a single dose of
15 mg/kg rituximab significantly increased the life expect-
ancy—50% of mice in this group survived 100 days—ul-
timately, tumours developed in all animals (an example is
shown in Fig. 4a) before the end of the observation period.
In contrast, the mice treated with the radioactive
149Tb-CHX-DTPA-rituximab (5 µg rituximab per ani-
mal) were almost completely protected over the entire
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Fig. 3. Survival graph of SCID mice grafted with 5·106 Daudi
cells i.v., followed by different i.v. treatments 2 days after xeno-
transplantation (for details see text)
observation period, with only one mouse in this group
being lost after 48 days due to abdominal tumour
growth. The remaining eight mice (89%) showed normal
behaviour without any signs of disease for 4 months af-
ter grafting (Fig. 4b). All of these mice were sacrificed
after 120 days and were found to be tumour free at dis-
section. Thus, a single injection of 5.5 MBq 149Tb-la-
belled rituximab (5 µg MoAb), which corresponds to an
injected dose of 280 MBq/kg body weight (7.5 mCi/kg),
produced long-term survival without evidence of any
disease at 120 days. The survival increase after the RIT
compared with all the control groups (no treatment, 5 µg
and 300 µg unlabelled rituximab) was highly significant
in the statistical Lee-Desu comparisons (P<0.005).
Biodistribution of labelled rituximab and the daughter
radionuclides
In Fig. 5 we present typical gamma spectra of retained
activity in organs recorded 120 days after injecting the
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Fig. 4 a. Dissected mouse from
the control group that received
300 µg rituximab, with clearly
visible large tumour in the ab-
domen (arrow). b Dissected
mouse grafted with Daudi cells
and treated by 149Tb-CHX-A-
DTPA-rituximab after 120
days, without any visible signs
of disease
Table 2. Biodistribution of
149Tb-labelled rituximab in
SCID mice 2 h after i.v. injec-
tion and of the remaining
daughter radioactivity distribu-
tion 120 days after injection
Organ 2 h p.i. 120 d p.i.
(% i.d./organ) (%/g tissue) (% i.d./organ) (%/g tissue)
Blood n.a. <0.01
Liver 18±3 24±4 1.8±0.3 1.6±0.2
Bonea 13±1 9.1±0.7 26±4 13±2
Spleen 1.9±0.2 42±4 0.40±0.06 12±2
Heart 4.7±0.7 41±6 <0.01
Lung 2.4±0.5 18±4 <0.01
Kidneyb 6±1 24±4 0.2±0.03 0.50±0.08
Muscles <0.2 <0.02
Bladderc 0.12±0.03 3.7±0.9 <0.01
Body, total 100 28.4±4
Note that both femurs and both kidneys were combined for the gamma spectroscopic measurements
in order to increase the signal to background ratio
n.a., Not done/not assessable
a Bone total was calculated as 9 × activity of both femora
b Both kidneys were measured together
c Bladder measured with urine
short-lived radio-immunoconjugate. The biodistribution
of 149Tb-CHX-A-DTPA-rituximab radio-immunoconju-
gate shortly after injection was assessed using a single
mouse sacrificed at 2 h. The retention of the long-lived
daughter nuclides at 120 days after injection is presented
in Table 2. After 2 h, the organs with high blood pool,
like the spleen, heart and kidney (42%, 41% and 24%
ID/g), showed relatively high radioactivity concentra-
tion. High amounts of the radio-immunoconjugate were
found in the liver at this time point (18%±3% injected
dose), confirming the results of earlier systematic studies
[20]. The values in the other organs were relatively low.
After 120 days, 71.6% of the primary injected radioac-
tive atoms had been excreted from the mice. The reten-
tion of the daughter products was 28.4%±4%, of which
91.1% remained in the bone tissue and 6.3% in the liver.
Discussion
Protection of mice treated with labelled rituximab
Here we show that TAT with rituximab labelled with the
high-purity alpha-emitting radio-lanthanide 149Tb led to
almost complete protection of xenografted mice over 4
months without detectable signs of toxicity, under condi-
tions where all animals in the control groups had to be
sacrificed during the observation period due to the devel-
opment of tumour diseases. The efficacy of the radionu-
clide bioconjugate as opposed to the unconjugated tu-
mour targeting antibody alone is underlined by the com-
plete lack of protection in the control group that received
5 µg unlabelled rituximab per animal, and the relatively
poor protection afforded by the higher dose unlabelled
rituximab group (300 µg per animal). The degree of pro-
tection afforded by the 149Tb-labelled rituximab indicates
that TAT with 149Tb is, on the basis of its efficacy, wor-
thy of further consideration as a novel radio-im-
munotherapeutic strategy.
Biodistribution of label and decay products
From earlier studies we have learnt that once the lan-
thanides are trapped in a tissue, like liver or bone, they
are fixed quite stably [20, 21]. The blood clearance for
free radio-lanthanides or radio-lanthanides injected in
solutions containing chelate ligands (citrate, EDTMP,
NTA, EDTA, DTPA and others) is fast (half-time <1 h)
[21, 22]. The radio-lanthanides are then present mainly
in the bone matrix and the liver, with the liver uptake de-
termined by the ionic radius of the lanthanide [21, 22,
23]. In the case of macromolecules (like monoclonal an-
tibodies) the blood clearance is slow (half-time ~1 day)
[20]. Thus, most of the 149Tb will decay while the la-
belled bioconjugate is in circulation and the free daugh-
ter nuclides formed in the radioactive decay would fol-
low the biodistribution known for free radio-lanthanides.
The biodistribution found 120 days after treatment corre-
sponds to the distribution patterns known for the free ra-
dio-lanthanide: highest daughter nuclide accumulation in
bone and liver (91.1% and 6.3% of the retained activity,
respectively) [21, 22]. The spleen shows a radioactivity
concentration almost as high as bone and significantly
higher compared with liver. We interpret this result as
evidence that the targeted and killed cancer cells are
eliminated mainly through the spleen, where the remain-
ing radioactive daughter atoms are then trapped.
The long-lived daughter products are formed along
two main decay processes: the isobar chain with A=145
is generated via the alpha decay mode of the initial
149Tb, while the isobar chain with A=149 is formed after
the EC- or β+-process. In the case of an alpha decay, the
recoil energy of the 145Eu daughter nuclei (110 keV) ex-
ceeds significantly the chemical binding energy. Conse-
quently, the original molecule, the antibody construct, is
destroyed and the daughter atom is initially stabilised as
free Eu3+ ion. In the case of the EC-decay mode, the
bound rupture is induced due to the Auger electron emis-
sion forming free daughter species [24, 25] with 100%
efficiency. However, it cannot be assumed that the
daughter species escapes from its place of origin; it
could eventually be bound to other proteins in the imme-
diate environment. Consequently, one may not necessari-
ly expect identical behaviour from daughter products
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Fig. 5. Typical gamma spectra of retained daughter radioactivity
in organs taken 120 days after injecting the radio-immunoconju-
gate into the mice
generated in the two different pathways: alpha or EC
process. Analysis of the gamma spectroscopic data re-
vealed that there was no statistically significant differ-
ence in the ratio of retained 145Sm to 149Eu in the organs
from that predicted by the branching ratio of 149Tb.
Thus, the radioactive decay pathway does not influence
the biodistribution or redistribution of the long-lived
daughter lanthanides.
Extrapolation to clinical application
A preliminary dose estimation for patients injected with
5 GBq 149Tb-rituximab was performed based on MIR-
DOSE 3.1 [26]. Assuming total decay of 149Tb-rituximab
in circulation and 100% retention of daughter nuclides in
the body with a bone uptake of 91%, the total equivalent
dose to the bone marrow as the critical organ would be
540 mSv/5 GBq (108 mSv/GBq) (see also Table 3).
149Tb itself would contribute 66.7% of the bone marrow
radiation dose (45.2% due to the α-radiation using an α-
radiation weight factor of WR=10) and 21.5% due to its
γ- and β+-radiation) while the daughter nuclides would
contribute 33.3% only. The dose contribution from
daughter nuclides estimated in this way represents a
worst-case estimation (assuming 100% retention), since
only 28.4% of the long-lived daughter products were re-
tained in mice 120 days p.i. Thus, injection of a poten-
tially therapeutic activity, 5 GBq 149Tb-rituximab, in a
70-kg patient, would deliver a bone marrow radiation
dose far below the critical level. This preliminary dose
estimation is well compatible with considerations pre-
sented in the review by McDevitt et al. [8].
For further reduction of the retention of the daughter
nuclides one could apply single or multiple injections of
chelating ligands like EDTA or DTPA during or shortly
after the treatment. This approach is already practiced as
a preventive action in treatments with 90Y- or 177Lu-
DOTATOC [27].
Time constraints and availability
Spallation reaction in combination with on-line mass
separator technology was used for the production of
149Tb for this study. The radiochemical separation and
purification of the 149Tb were relatively easy to perform
in about 30 min in this specific case, since we started
from non-carrier-added preparations. The final 149Tb
preparation was obtained in very high purity and in a
small volume, and the labelling of the bioconjugate was
fast (10 min) and almost quantitative. The administration
of the preparation should be carried out as rapidly as
possible after purification of the 149Tb, since levels of
contamination with daughter nuclides will increase with
time. For example, application of a fixed dose of the
149Tb-labelled bioconjugate 4 h after the final purifica-
tion of the isotope itself (EOS) leads to an increase in the
long-lived daughter content by a factor of 2. According
to the preliminary dose estimation one could define a
shelf-life for the 149Tb-labelled bioconjugate of about
4–6 h. For a longer delay it would be advisable to repuri-
fy the 149Tb from the accumulated daughter products, a
process that could require 30 min.
Several nuclear processes could be used to make this
interesting alpha-emitting isotope available on large
scale: light particle (p, d, He)-induced reactions on 152Gd
as target material, heavy ion-induced reactions on light
lanthanide targets or spallation reaction on Ta as target
[19]. Off-line and on-line mass separation process may
support a very high isotopic purity [19, 28].
For the time being, only a few centres may be able to
make this isotope. On the other hand, all the above-men-
tioned technologies are well developed and available to-
day. In summary, should 149Tb continue to show promise
in further studies of TAT, then it would be technically
feasible to make the isotope available on a large scale
and on a routine basis.
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Table 3. Radioactivity level of long-lived daughter products retained in a patient after injection of 1 GBq 149Tb-rituximab antibodies, as-
suming 100% retention of the long-lived daughter products (worst case)
t p.i. 149Tb 149Gd 149Eu 145Eu 145Sm 145Pm
T 1/2=4.12 h 9.28 days 93.1 days 5.93 days 340 days 17.7 yrs
=0 1.0 GBq
2 days 310 kBq 13 MBq 0.2 MBq 3.9 MBq 18 kBq
5 days 11 MBq 0.4 MBq 2.7 MBq 37 kBq 43 Bq
10 days 7.3 MBq 0.7 MBq 1.5 MBq 57 kBq 86 Bq
100 days 8 kBq 0.7 MBq 41 Bq 70 kBq 0.8 kBq
1 yr 0.1 MBq 41 kBq 2.2 kBq
10 yrs 0 50 Bq 3.1 kBq
The retention was measured to be only 28.4% independent of the
decay mode (alpha or EC) (see Table 2); thus the real activity of
daughter products would be nearly a factor of 4 smaller. On the
other hand, the injection of a 149Tb-labelled bioconjugate 4 h after
the Tb purification would increase the activity of the daughter
product by a factor of 2. In this way the numbers in this table can
still be seen as upper limits
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